



Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing researchers' discoveries to the public, but can present the potential for conflicts of interest with respect to their research activities.

Cleveland Clinic has policies and procedures in place to identify potential conflicts of interest to safeguard the objectivity of research taking place at Cleveland Clinic. Cleveland Clinic requires any person who is responsible for the design, conduct or reporting of Public Health Service (PHS)-funded research at Cleveland Clinic to disclose their outside financial interests every year as well as whenever there is a change to their interests. Cleveland Clinic's Innovation Management and Conflict of Interest Program reviews all disclosures in relation to the researchers' proposed and ongoing research projects to determine whether the financial interests are related to the research activities and whether they create a PHS-Reportable Financial Conflict of Interest.

Cleveland Clinic, its physicians and scientists advocate transparency with respect to relationships with industry. Accordingly, Cleveland Clinic provides the public certain information regarding PHS-Reportable Financial Conflicts of Interest via this webpage.

As PHS grants come up for funding or renewal, they will be evaluated for potential PHS-Reportable Financial Conflicts of Interest. As these are identified, they will be listed on this page. Cleveland Clinic will maintain this listing by updating it at least annually and whenever a new PHS-Reportable Financial Conflicts of Interest is identified.

As of September 7, 2021, Cleveland Clinic has identified the following Public Health Service-Reportable Financial Conflicts of Interest under *Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors*, 76 Fed. Reg. 53,256 (Aug. 25, 2011) (codified at 42 C.F.R. Part 50 Subpart F and 42 C.F.R. Part 94).

Maciej Zborowski, Ph.D.

Principal Investigator

Dr. Zborowski is entitled to a portion of any royalty payments Cleveland Clinic receives from IKOtech, LLC, Precelleon, Inc. and Ward Engineering for technology he developed. In the previous 12-months, Dr. Zborowski received between \$0 - \$4,999.

Imre Noth, M.D.

The University of Chicago Subaward Principal Investigator

Dr. Noth disclosed receiving \$10,000 - \$19,999 in payment for consulting services from Immuneworks, Inc. in the previous 12-months. Dr. Noth also has

Intellectual Property rights for technology licensed to Celgene Corporation from the University of Pittsburgh. In the previous 12-months, Dr. Noth received between \$0 - \$4,999 from Celgene.

Stanley Hazen, M.D., Ph.D.

Principal Investigator

Dr. Hazen disclosed receiving \$200,000 - \$299,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Cleveland HeartLab, Inc. as well as holding equity in the company with an estimated value between \$10,000 - \$19,999.

Stanley Hazen, M.D., Ph.D.

Principal Investigator

Dr. Hazen disclosed receiving \$20,000 - \$39,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Liposcience, Inc. Dr. Hazen disclosed receiving \$40,000 - \$59,999 in fees for services from the company in the previous 12-months.

Stanley Hazen, M.D., Ph.D.

Principal Investigator

Dr. Hazen disclosed receiving \$5,000 - \$9,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Esperion Therapeutics, Inc. Dr. Hazen disclosed receiving \$20,000 - \$39,999 in fees for services from the company in the previous 12-months.

Zeneng Wang, Ph.D.

Project Scientist

Dr. Wang discloses receiving \$0 - \$4,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Liposcience, Inc.

Renliang Zhang, M.D., Ph.D.

Core Director

Dr. Zhang disclosed receiving \$40,000 - \$59,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Cleveland HeartLab, Inc.

Courtenay Moore, M.D.

Co-Investigator

Dr. Moore disclosed receiving \$0 - \$4,999 from Allergan, Inc. in the previous 12-months as consideration for serving on a scientific advisory board and for serving as a speaker, trainer or educator.

Jaroslaw Maciejewski, M.D., Ph.D., FACP

Co-Investigator

Dr. Maciejewski disclosed receiving \$10,000 - \$19,999 from Eisai Co., Ltd. in the previous 12-months as consideration for serving as a speaker, trainer or educator.

Jonathan Smith, Ph.D.

Project Director

Dr. Smith disclosed receiving \$20,000 - \$39,999 in royalty payments for technology he developed and Cleveland Clinic licensed to Esperion Therapeutics, Inc. Dr. Smith disclosed receiving \$20,000 - \$39,999 in fees for services from the company in the previous 12-months.

Anthony Calabro, Jr., Ph.D.

Co-Investigator

Dr. Calabro is entitled to a portion of any royalty payments Cleveland Clinic receives from Lifecore Biomedical, LLC for technology he developed. In the previous 12-months, Dr. Calabro received between \$0 - \$4,999.

William J. Dupps, Jr., M.D., Ph.D.

Principal Investigator

Dr. Dupps disclosed receiving \$10,000 - \$19,999 in commercialization revenues from Avedro, Inc. in the previous 12-months for technology he developed. Cleveland Clinic and Avedro entered into an exclusive option agreement for this technology.

Andrew Rollins, Ph.D.

Case Western Reserve University Co-Investigator

Dr. Rollins disclosed receiving \$0 - \$4,999 in commercialization revenues from OptoQuest, Inc. in the previous 12-months for technology he developed. Cleveland Clinic and Avedro entered into an exclusive option agreement for this technology.

Philip Schauer, M.D.

Co-Principal Investigator

Dr. Schauer disclosed receiving \$10,000 - \$19,999 in payments for services from Ethicon Endo-Surgery, Inc. in the previous 12-months.

Sandip Vasavada, M.D.

Co-Investigator

Dr. Vasavada disclosed receiving \$10,000 - \$19,999 from Medtronic, Inc. in the previous 12-months as consideration for serving as a speaker, trainer or educator.

Jaroslav Maciejewski, M.D., Ph.D., FACP

Co-Investigator

Dr. Maciejewski disclosed receiving \$10,000 - \$19,999 from Celgene Corporation in the previous 12-months as consideration for serving as a speaker, trainer or educator.

Miriam Cremer, M.D., M.P.H.

Principal Investigator

Dr. Cremer disclosed receiving \$200,000 - \$250,000 in the previous 12-months from Basic Health International for serving as founder and global head of clinical and medical services.

Vinod Labhasetwar, Ph.D.

Principal Investigator

Dr. Labhasetwar disclosed holding equity in ProTransit Nanotherapy, LLC. The financial interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

A. Marc Gillinov, M.D.

Principal Investigator

Dr. Gillinov disclosed receiving \$20,000 - \$39,999 from Edwards Lifesciences, LLC in the previous 12-months as consideration for serving as a consultant and speaker, trainer or educator.

Jose Navia, M.D.

Co-Investigator

Dr. Navia disclosed receiving \$5,000 - \$9,999 from Edwards Lifesciences, LLC in the previous 12-months for serving as a speaker, trainer or educator.

Douglas Johnston, M.D.

Co-Investigator

Dr. Johnston disclosed receiving \$5,000 - \$9,999 from Edwards Lifesciences, LLC in the previous 12-months for serving as a speaker, trainer or educator.

Jan Jensen, Ph.D.

Principal Investigator

Dr. Jensen disclosed holding equity in a non-publicly traded entity. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Andre Machado, M.D., Ph.D.

Principal Investigator

Dr. Machado disclosed holding equity in a non-publicly traded entity, Enspire DBS Therapy, Inc. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Yogen Saunthararajah, M.D.

Investigational New Drug (IND) Holder

Dr. Saunthararajah disclosed receiving \$0 - \$4,999 in commercialization revenues from Epidestiny, LLC and DeNovoTherapies, LLC for technology he developed. University of Illinois Chicago entered into a license agreement for this technology.

Edward Plow, Ph.D.

Principal Investigator

Dr. Plow disclosed holding equity in a non-publicly traded entity, Sujana Biotech, LLC. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Jeffrey Cummings, M.D.

Principal Investigator

Dr. Cummings disclosed an immediate family member's receipt of salary of \$100,000 - \$149,999 from the Global Alzheimer's Platform Foundation.

David Horvath, M.S.M.E.

Consultant

Mr. Horvath is entitled to a portion of any commercialization revenues Cleveland Clinic receives from Cleveland Heart Inc. for technology he developed. In the previous 12-months, Mr. Horvath received between \$0 - \$4,999.

Justis Ehlers, M.D.

Principal Investigator

Dr. Ehlers disclosed receiving \$10,000 - \$19,000 from Leica Microsystems GmbH in consulting compensation in the previous 12-months.

Li Wang, Ph.D.

Principal Investigator

Dr. Wang disclosed receiving \$60,000 - \$79,999 in commercialization revenues from Immunext, Inc. through Dartmouth College.

George Muschler, M.D.

Principal Investigator

Dr. Muschler disclosed holding equity in a non-publicly traded entity, Cell X Technologies, Inc. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. He is also entitled to a portion of any commercialization revenues Cleveland Clinic receives from Cell X Technologies, Inc. In the previous 12-months, Dr. Muschler received between \$0 - \$4,999.

Nathan Pennell, M.D.

Principal Investigator

Dr. Pennell disclosed receiving \$10,000 - \$19,999 from Merck and Co., Inc. for serving on a scientific advisory board or other research advisory board committee in the previous 12-months.

Jay Alberts, Ph.D.
Principal Investigator

Dr. Alberts disclosed holding equity in a non-publicly traded entity, Qr8 Health, Inc. The value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. He is also entitled to a portion of any commercialization revenues Cleveland Clinic receives from Qr8 Health, Inc. In the previous 12-months, Dr. Alberts received between \$0 and \$4,999.

Yogen Sauntharajah, M.D.
Principal Investigator

Dr. Sauntharajah disclosed holding equity valued at \$30,000,000 - \$30,050,000 (currently in dispute) and receiving \$0 - \$4,999 in commercialization revenues from Epidestiny, LLC and DeNovoTherapies, LLC for technology he developed. University of Illinois Chicago entered into a license agreement for this technology.

Daniel Blankenberg, Ph.D.
Principal Investigator

Dr. Blankenberg disclosed holding equity in a non-publicly traded entity, Galactic Core, LLC., (now GalaxyWorks), valued at \$0 - \$4,999. He is a founder and initial investor in the company.

Viviane Luangphakdy
Research Engineer

Ms. Luangphakdy disclosed \$80,000 - \$99,999 in salary from Cell X Technologies, Inc.

Aaron Gerds, M.D.
Principal Investigator

Dr. Gerds disclosed receiving \$5,000 - \$9,999 from Celgene Corporation for serving on a scientific advisory board or other research advisory board committee in the previous 12-months.

Karl West, M.S.
Principal Investigator

Mr. West disclosed holding equity in a non-publicly traded entity, Centerline Biomedical, valued at \$40,000 - \$59,999. Mr. West also disclosed consulting fees of \$20,000 - \$39,999 in the previous 12-months.

Jeffrey Yanof, Ph.D.
Co-Investigator

Dr. Yanof disclosed receiving \$5,000 - \$9,999 from Centerline Biomedical for serving as a consultant in the previous 12 months.

Rishi Puri, M.D., Ph.D.

Co-Investigator

Dr. Puri disclosed holding equity in a non-publicly traded entity, Centerline Biomedical, valued at \$0 - \$4,999.

Kenneth Baker, Ph.D.

Co-Investigator

Dr. Baker disclosed holding equity in a non-publicly traded entity, Enspire DBS Therapy, Inc., valued at \$0 - \$4,999.

Timothy Chan, M.D.

Principal Investigator

Dr. Chan disclosed holding equity in a publicly traded entity, Gritstone Oncology, valued at \$250,000 - \$300,000 and intellectual property rights of \$0 - \$4,999. Dr. Chan also disclosed receiving \$20,000-\$40,000 in royalties from Personal Genome Diagnostics, Inc..

Shilpa Gupta, M.D.

Principal Investigator

Dr. Gupta disclosed receiving \$5,000 - \$9,999 from Pfizer, Inc. for serving on a scientific advisory board or other research advisory board committee in the previous 12-months.

Nathan Pennell, M.D.

Principal Investigator

Dr. Pennell disclosed receiving \$5,000 - \$9,999 from Genentech, Inc. for serving on a scientific advisory board or other research advisory board committee in the previous 12-months.

Babak Tousi, M.D.

Principal Investigator

Dr. Tousi disclosed receiving \$0 - \$4,999 from Biogen Idec, Inc. for serving as a consultant in the previous 12 months.

Vladimir Makarov, M.D.

Co-Investigator

Dr. Makarov disclosed having intellectual property rights from Gritstone Oncology valued at \$5,000 - \$9,999 in the previous 12-months.

Stanley Hazen, M.D., Ph.D.

Principal Investigator

Dr. Hazen disclosed being an inventor of technology Cleveland Clinic optioned to Zehna Therapeutics, Inc. and holding equity in the company for consulting

services. The company is non-publicly traded and the value of the equity cannot be readily ascertained. He anticipates consulting compensation from the company as well.